Abstract:BACKGROUND: The function of the tumor suppressor gene RASSF1A in cancer cells has been detailed in many studies. However, due to the methylation of its promoter, the expression of RASSF1A is missing in most cancers. In the literature, we found that the conclusion regarding the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma was not unified. This study adopts the use of a meta-analysis and bioinformatics to explore the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma.METHODS: Data on melanoma susceptibility were downloaded from the PubMed, Cochrane Library, Web of Science and Google Scholar databases, which were analyzed via a meta-analysis. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). We also used a chi-squared-based Q test to examine the between-study heterogeneity, and used funnel plots to evaluate publication bias. The data on melanoma prognosis, which were analyzed by bioinformatics methods, were downloaded from The Cancer Genome Atlas (TCGA) project. The effect sizes were estimated by measuring the hazard ratios (HRs) with a 95% confidence interval (CI).RESULTS: Our meta-analysis included 10 articles. We found that RASSF1A gene promoter methylation was closely related to melanoma susceptibility (OR = 12.67, 95% CI: 6.16 ∼ 26.05, z = 6.90, P<0.0001 according to a fixed effects model and OR = 9.25, 95% CI: 4.37 ∼ 19.54, z = 5.82, P<0.0001 according to a random effects model). The results of the meta-analysis did not reveal any heterogeneity (tau2 = 0.00; H = 1 [1; 1.55]; I2 = 0% [0%; 58.6%], P = 0.5158) or publication bias (t = 0.87, P = 0.4073 by Egger's test; Z = 0.45, P = 0.6547 by Begg's test); therefore, we believe that the results of our meta-analysis were more reliable. To explore the relationship between RASSF1A gene methylation, the prognosis of melanoma and the clinical features of this cancer type, we used the melanoma DNA methylation data and clinical data from TCGA project. We found that RASSF1A gene promoter methylation and melanoma prognosis did not demonstrate any relationship (HR was 0.94 (95% CI = [0.69; 1.27], P = 0.694) with disease-free survival and 0.74 (95% CI = [0.53; 1.05], P = 0.106) for overall survival), and no significant difference was observed between RASSF1A gene promoter methylation and the clinical-pathological features of melanoma.CONCLUSIONS: In conclusion, the meta-analysis of the data in these articles provides strong evidence that the methylation status of the RASSF1A gene promoter was strongly related to melanoma susceptibility. Our bioinformatics analysis revealed no significant difference between RASSF1A gene promoter methylation and the prognosis and clinical-pathological features of melanoma.

Association of Rassf1a Promoter Methylation with Gastric Cancer Risk: A Meta-Analysis

Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.

The Association Of Ras Association Domain Family Protein1a (Rassf1a) Methylation States And Bladder Cancer Risk: A Systematic Review And Meta-Analysis

The Association Between RASSF1A Promoter Methylation and Prostate Cancer: Evidence from 19 Published Studies

RASSF1A Promoter Methylation is Associated with Increased Risk of Thyroid Cancer: a Meta-Analysis

Association of Diminished Expression of RASSF1A with Promoter Methylation in Primary Gastric Cancer from Patients of Central China.

Detection of Serum RASSF1A Gene Promoter Methylation in Patients with Gastric Cancer

Association Between Rassf1a Promoter Methylation And Prostate Cancer: A Systematic Review And Meta-Analysis

An analysis of the relationship between the methylation of RASSF1A gene and gastric cancer

Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.

Methylation of ras association domain protein 10 (RASSF10) promoter negative association with the survival of gastric cancer.

RASSF1A promoter methylation correlates development, progression, and poor cancer-specific survival of renal cell carcinoma: trial sequential analysis.

Detection of Rassf1a Promoter Hypermethylation in Serum from Gastric and Colorectal Adenocarcinoma Patients

The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics

Hypermethylation and clinicopathological significance of RASAL1 gene in gastric cancer.

CHFR Promoter Hypermethylation is Associated with Gastric Cancer and Plays a Protective Role in Gastric Cancer Process

Mrna Expression and Promoter Hypermethylation Status of RASSF1A in Lung Carcinoma

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

A meta-analysis of association between RUNX3 gene promoter methylation and gastric cancer

Aberrant Methylation of RASSF1A Gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis.